Table 1. Proportion of funding under the consecutive CPAs.
| 1st CPA (1990–1995) |
2nd CPA (1995–2000) |
3rd CPA (2000–2005) |
4th CPA (2005–2010) |
5th CPA (2010–2015) |
6th CPA (2015–2020) |
|
|---|---|---|---|---|---|---|
| Total fundinga, (% increase from previous CPA) | $3.286 billion | $5.497 billion (↑67%) | $8.804 billion (↑60%) | $12.158 billion (↑38%) | $15.610 billion (↑28%) | $18.886 billion (↑21%) |
| Funding for Pharmacy Remunerationb, (% within the CPA) | Not Available | Not Available | $5.6 billion (63%) | $11.1 billion (91%) | $13.8 billion (89%) | $14.8 billion (78%) |
| Funding for CPS, (% within the CPA) | $114 million (1.29%) | $241 million (1.98%) | $427 million (2.77%) | $368 millionc (1.94%) | ||
| Funding for R&D, (% within the CPA) | $5 million (0.1%) | $15 million (0.17%) | $19 million (0.16%) | $11 million (0.06%) | $50 milliond (0.26%) |
aActual expenditure under each agreement was not publicly reported. These numbers were obtained from the Audit Report on the Administration of the 5th CPA;
bFunding that was related only to payment for supplying the medicines e.g. dispensing fee, pharmacy mark-up, premium fee dispensing incentives, extemporaneous preparation etc.;
cApproximately $613 million was invested in the 6th CPA under funding for Community Pharmacy Programs. However, only half of this funding was allocated for provision of professional pharmacy services as indicated in Appendix B of the agreement. Additional funding up to $600 million will be provided based on the recommendations of the Health Technology Assessment Body after evaluating the outcome of the Pharmacy Trials Program.
d Funding for the R&D program was ceased in the 6th CPA and shifted to fund the Pharmacy Trial Program.